Astrazeneca (AZN) Other Non-Current Assets (2011 - 2025)

Astrazeneca (AZN) has reported Other Non-Current Assets for 11 consecutive years, with $559.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Non-Current Assets rose 57.02% year-over-year to $559.0 million; the TTM figure through Dec 2025 stood at $559.0 million (up 57.02% YoY), while the FY2025 annual figure was $559.0 million, up 57.02% from the prior year.
• Other Non-Current Assets came in at $559.0 million for Q4 2025 at Astrazeneca, up from $356.0 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $559.0 million in Q4 2025, with the low at -$447.0 million in Q1 2021.
• Average Other Non-Current Assets over 5 years is $229.3 million, with a median of $315.0 million recorded in 2023.
• Across the five-year window, Other Non-Current Assets tumbled 557.47% in 2021 and jumped 57.02% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $391.0 million in 2021, then plunged by 37.85% to $243.0 million in 2022, then grew by 12.76% to $274.0 million in 2023, then gained by 29.93% to $356.0 million in 2024, then surged by 57.02% to $559.0 million in 2025.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $559.0 million, $356.0 million, and $274.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.